logo
logo
Exact Sciences Corporation

Exact Sciences Corporation

NASDAQ•EXAS
CEO: Mr. Kevin T. Conroy J.D.
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 2001-02-01
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
連絡先情報
5505 Endeavor Lane, Madison, WI, 53719, United States
608-284-5700
www.exactsciences.com
時価総額
$19.61B
PER (TTM)
-19.8
21.2
配当利回り
--
52週高値
$103.54
52週安値
$38.81
52週レンジ
100%
順位62Top 92.6%
1.9
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.9 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$850.74M+20.05%
直近4四半期の推移

EPS

-$0.10-52.38%
直近4四半期の推移

フリーCF

$190.03M+68.82%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth Strong Nine months revenue reached $2.37B, showing 15.8% increase driven by Cologuard volume growth and new launches.
Operating Cash Flow Surge Cash provided by operations totaled $339.7M for nine months, improving $176.3M versus prior year period results.
Net Loss Significantly Reduced Nine months net loss narrowed to $(122.0M) compared to $(164.3M) loss last year, indicating improved performance.
New Product Launches Complete Launched Cologuard Plus in March 2025 and Cancerguard in September 2025, expanding screening portfolio access.

リスク要因

Ongoing Profitability Concerns Accumulated deficit reached $4.62B as of September 30, 2025; sustained profitability remains uncertain despite improvements.
Productivity Plan Costs Incurred $72.6M in restructuring and business transformation charges through September 30, 2025 period for efficiency efforts.
FDA Review Delays Risk Government shutdowns or policy changes may slow FDA review, potentially delaying new product approvals impacting operations.
Contingent Consideration Valuation Contingent consideration liability stands at $284.1M, valued using Level 3 unobservable inputs requiring management judgment.

見通し

Productivity Plan Savings Goal Multi-year plan aims for over $150.0M in expected annual savings by 2026 via general and administrative efficiencies.
Pipeline Advancement Focus Prioritize launching Cologuard Plus, Oncodetect, and Cancerguard tests while investing in clinical trial enhancements.
Credit Facility Available Secured $500.0M Revolving Credit Facility in January 2025; no funds drawn as of September 30, 2025.
Continuing Revenue Growth Expected Expect revenue growth for Cologuard and Oncotype tests, subject to seasonality, payer mix, and new product adoption.

同業比較

売上高 (TTM)

Viatris Inc.VTRS
$14.12B
-6.1%
Baxter International Inc.BAX
$11.24B
+5.7%
ICON Public Limited CompanyICLR
$8.10B
-2.5%

粗利益率 (最新四半期)

Ionis Pharmaceuticals, Inc.IONS
98.5%
-0.7pp
BridgeBio Pharma, Inc.BBIO
94.6%
+16.5pp
Doximity, Inc.DOCS
89.9%
+0.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
EXAS$19.61B-19.8-40.4%43.0%
ROIV$18.93B-22.8-18.3%4.0%
RVMD$18.62B-19.0-49.2%7.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
6.0%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月18日
|
EPS:-
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月3日|
    売上高: $850.74M+20.1%
    |
    EPS: $-0.10-52.4%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $811.09M+16.0%
    |
    EPS: $-0.01-92.7%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月1日|
    売上高: $706.79M+10.9%
    |
    EPS: $-0.54-10.0%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月19日|
    売上高: $2.76B+10.4%
    |
    EPS: $-5.59-394.7%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月5日|
    売上高: $708.66M+12.8%
    |
    EPS: $-0.21-4872.7%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年7月31日|
    売上高: $699.26M+12.4%
    |
    EPS: $-0.09-80.9%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月8日|
    売上高: $637.52M+5.8%
    |
    EPS: $-0.60+42.9%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月21日|
    売上高: $2.50B+19.9%
    |
    EPS: $-1.13+68.1%
    予想を上回る